Breast Journal最新文献

{"title":"Circulating Plasma Circular RNAs hsa_circ_0001785 and hsa_circ_0079876 as Promising Noninvasive Diagnostic Biomarkers for Breast Cancer: A Case–Control Study","authors":"Amirhossein Sangi Nasab Lahijan,&nbsp;Sepideh Abdollahi,&nbsp;Seyed Rohollah Miri,&nbsp;Ghasem Azizi-Tabesh,&nbsp;Mir Saeed Yekaninejad,&nbsp;Pantea Izadi","doi":"10.1155/tbj/8008795","DOIUrl":"10.1155/tbj/8008795","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Breast cancer (BC) is a major health concern for women, with early diagnosis essential for better health outcomes such as survival. While mammography is the gold standard screening tool, it is not without drawbacks. Circular RNAs (circRNAs), a class of noncoding RNAs, characterized by covalently closed loops missing 5′ and 3′ ends, offer stability in body fluids like plasma and are emerging as promising diagnostic biomarkers. Thus, the aim of this study was to investigate the plasma levels of hsa_circ_0001785 and hsa_circ_0079876 in BC patients compared to healthy controls to evaluate their potential for noninvasive BC detection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 129 women participated in this study (81 BC patients who underwent surgery and 48 healthy controls based on mammography). The plasma levels of hsa_circ_0001785 and hsa_circ_0079876 were measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR) following RNA extraction from plasma samples. The diagnostic value was assessed using the receiver operating characteristic (ROC) curve.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significant increase in the expression of both circRNAs was observed in BC patients compared with healthy controls (<i>p</i> value &lt; 0.001). ROC curve analysis demonstrated that an area under the curve (AUC) for hsa_circ_0001785, hsa_circ_0079876, and their combination were 0.76 (sensitivity = 74%, specificity = 79%), 0.98 (sensitivity = 93%, specificity = 92%), and 0.98 (sensitivity = 93%, specificity = 92%), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Plasma levels of hsa_circ_0001785 and hsa_circ_0079876 are significantly elevated in BC patients, with hsa_circ_0079876 showing superior sensitivity and specificity compared to hsa_circ_0001785. These findings highlight hsa_circ_0079876 as a particularly promising diagnostic potential in a case–control setting for noninvasive BC detection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/8008795","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review and Meta-Analysis: Association Between Circulating and Tissue Levels of Selenium and Zinc and Breast Cancer Risk","authors":"Adrienne Pratti Lucarelli,&nbsp;Maria Marta Martins,&nbsp;Mariana Mie Teruya,&nbsp;Thaís Tiemi Yauti,&nbsp;Daniela Rie Hayashi","doi":"10.1155/tbj/7448703","DOIUrl":"10.1155/tbj/7448703","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Selenium (Se) and zinc (Zn) are essential micronutrients that play roles in antioxidant defense and the regulation of cell proliferation. Increasing evidence suggests that disturbances in trace element balance may contribute to breast carcinogenesis; however, findings across studies remain inconsistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the association between circulating and tissue Se and Zn levels and breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review and meta-analysis were conducted according to PRISMA 2020 and MOOSE recommendations. Searches were performed in MedLine, EMBASE, and LILACS from database inception until April 15, 2026. Case–control studies comparing selenium and zinc levels between women with breast cancer and control groups were eligible. Two independent reviewers performed study selection, data extraction, risk-of-bias assessment, and publication bias analysis using Egger’s regression test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty case–control studies were included. Most studies (83.3%) were classified as high methodological quality according to the Newcastle–Ottawa Scale. Meta-analyses revealed significantly lower selenium levels in plasma (MD = −12.10 μg/L; 95% CI: −17.54 to −6.65; <i>p</i> &lt; 0.0001), selenium in nails (MD = −0.02 μg/g; 95% CI: −0.04 to −0.01; <i>p</i> = 0.006), and zinc in plasma (MD = −0.33; 95% CI: −0.47 to −0.19; <i>p</i> &lt; 0.00001) in breast cancer patients compared with controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The pooled findings indicate an inverse association between breast cancer and selenium levels measured in plasma and nails, as well as plasma zinc concentrations. Nevertheless, interpretation should remain cautious because all included studies had observational designs, with marked heterogeneity and potential residual confounding. Lower circulating selenium and zinc levels, together with reduced selenium concentrations in nails, were associated with breast cancer occurrence. Additional prospective studies are required to clarify causality and determine the clinical significance of these associations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7448703","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148370960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer","authors":"Poorni M. Manohar,&nbsp;Veena Shankaran,&nbsp;Nancy E. Davidson,&nbsp;Natasha Hunter,&nbsp;William R. Gwin,&nbsp;Rachel L. Yung,&nbsp;Jennifer M. Specht,&nbsp;Catherine Federenko,&nbsp;Sun Qin,&nbsp;Qian (Vicky) Wu,&nbsp;Jenna M. Voustinas,&nbsp;Josh A. Roth,&nbsp;Hannah M. Linden","doi":"10.1155/tbj/4333748","DOIUrl":"10.1155/tbj/4333748","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Intro</h3>\u0000 \u0000 <p>Divergence from national guidelines and variations in practice patterns impact care and outcomes in patients with metastatic breast cancer (MBC). We sought to assess the quality of care in the diagnosis and treatment of real-world patients with MBC in Washington State.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were retrospectively analyzed using a linked cancer registry and insurance claims platform for patients with recurrent or de novo MBC diagnosed between 2008 and 2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 1101 patients with MBC (median age: 66), 715 recurrent and 386 de novo. Most patients were White (89%), all were insured (Commercial [47%], Medicaid [4%], Medicare [35%], or multiple [13%]), and 15% lived in areas of high deprivation (Area Deprivation Index [ADI]: 8–10). Of the patients with recurrent MBC, less than half received a biopsy (49.5%) or biomarker reassessment (48.7%) to confirm the diagnosis of MBC. Patients treated at high- and medium-volume centers had higher rates of biopsy than low-volume clinics (51.9%, 54.3%, and 40.7%, respectively, <i>p</i> = 0.03). ET alone was more common in patients who did not undergo biopsy (62.3% vs. 37.7%, <i>p</i> &lt; 0.001) or biomarker reassessment (62.7% vs. 37.3%, <i>p</i> &lt; 0.001). Among the 677 patients with estrogen receptor (ER)+/HER2− MBC (de novo and recurrent), most received ET alone (69%), followed by CT (22%) and CDKi + ET (9%). Importantly, 40% of patients were treated before CDK4/6i approval. Most patients who received CDKi + ET were &lt; 65 years old (65.2%, <i>p</i> &lt; 0.02). Patients with commercial insurance were more likely to receive CDKi + ET compared to those with Medicare/Medicaid. (60.9% vs. 26.1%, <i>p</i> = 0.10).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings highlight key gaps in MBC management and serve as a launch point for patient-centered and quality-promoting initiatives.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/4333748","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Preoperative Radiological Tumor Size Underestimation in Clinical T1–2 Breast Cancer Patients","authors":"Jungbin Kim,&nbsp;Yujin Lee,&nbsp;Sam-Youl Yoon,&nbsp;Hyunjin Cho,&nbsp;Ye Young Seo,&nbsp;Ji-Young Kim,&nbsp;Young-Joo Shin,&nbsp;Kyeongmee Park,&nbsp;Geumhee Gwak","doi":"10.1155/tbj/3726326","DOIUrl":"https://doi.org/10.1155/tbj/3726326","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Accurate preoperative tumor size measurement is essential for determining optimal surgical margins in breast cancer patients. Thus, this study aimed to evaluate the factors associated with preoperative radiological tumor underestimation in clinical T (cT) Stage 1–2 breast cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed the data of 365 cT1–2 breast cancer patients. Radiological tumor size was defined as the larger dimension on ultrasonography or magnetic resonance imaging. A pathological-to-radiological tumor size ratio &gt; 1.2 or a tumor size discrepancy (pathology minus radiology) ≥ 5 mm was considered indicative of radiological underestimation. Preoperative variables, including age, body mass index (BMI), cT stage, maximum standardized uptake value of tumor, molecular subtype, and histologic subtype and grade, were analyzed to identify associated factors. Tumor size discrepancy (pathology minus radiology) was compared across subgroups, and the difference between pathological and radiological tumor size measurements was evaluated in each subgroup.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A BMI ≥ 25 kg/m² (<i>p</i> = 0.006) and invasive lobular carcinoma (ILC) histology (<i>p</i> = 0.030) were associated with a pathological-to-radiological tumor size ratio &gt; 1.2. A BMI ≥ 25 kg/m² (<i>p</i> = 0.015), ILC histology (<i>p</i> = 0.022), and cT stage (<i>p</i> = 0.027) were associated with a tumor size discrepancy (pathology minus radiology) ≥ 5 mm. Significant differences in tumor size discrepancy between patients with a BMI ≥ 25 kg/m² and those with a BMI &lt; 25 kg/m² (<i>p</i> = 0.003) and between patients with an ILC and those with non-ILC (<i>p</i> = 0.041) were observed. Bland–Altman analysis showed radiological underestimation in ILCs (4.3 mm).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In cT1–2 breast cancer patients, a BMI ≥ 25 kg/m² and/or an ILC are predictive of radiological tumor underestimation, warranting supplemental imaging and intraoperative margin assessment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/3726326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148324908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Side Effects of Breast Cancer Treatments: A Systematic Review","authors":"Ebrahim Babaee,&nbsp;Mahdi Soheyli,&nbsp;Nahid Nafissi","doi":"10.1155/tbj/6873605","DOIUrl":"10.1155/tbj/6873605","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer treatments, including chemotherapy, radiotherapy, endocrine therapy, targeted therapy, and surgical interventions, have significantly improved survival rates. However, these treatments are associated with long-term side effects that can impact the quality of life of survivors. Understanding these adverse effects is crucial for optimizing survivorship care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This systematic review was conducted following PRISMA guidelines to assess the long-term side effects of breast cancer treatments. A comprehensive literature search was performed for studies published between 2005 and 2024. Studies examining long-term (≥ 12 months posttreatment) adverse effects in breast cancer survivors were included, with data extraction and risk of bias assessments conducted by independent reviewers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review identified a broad spectrum of long-term side effects, including cardiovascular complications, cognitive impairment, persistent fatigue, lymphedema, menopausal symptoms, and psychological distress. Chemotherapy was frequently associated with peripheral neuropathy and cognitive decline, while radiotherapy increased the risk of fibrosis, secondary malignancies, and ischemic heart disease. Endocrine therapy contributed to osteoporosis, joint pain, and metabolic disturbances, whereas HER2-targeted therapies were linked to cardiotoxicity. In addition, surgical interventions, particularly axillary lymph node dissection, were a primary cause of lymphedema. Psychological distress, including anxiety, depression, and posttraumatic stress disorder, was also prevalent among survivors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The long-term side effects of breast cancer treatments highlight the need for comprehensive survivorship care, including routine monitoring, personalized rehabilitation programs, lifestyle modifications, and psychosocial support. Future research should focus on identifying risk factors, developing targeted interventions, and optimizing treatment strategies to minimize adverse effects and improve the quality of life for breast cancer survivors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6873605","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148320409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0","authors":"Anushree R. Iyengar,&nbsp;Erinn P. Downs,&nbsp;Sandhya Mehta,&nbsp;Nivedita Rangarajan,&nbsp;Michele Sue-Ann Woo,&nbsp;Simone T. Sredni,&nbsp;Rosemarie Di Donato,&nbsp;Safak Simsek,&nbsp;Darren M. Wilson,&nbsp;Katherine Krieser,&nbsp;Elise Bieri Patzke,&nbsp;Natalie Kyek,&nbsp;Christian Anderson,&nbsp;Tyler Wagner,&nbsp;Jason Hipp,&nbsp;Aziza Nassar,&nbsp;Hannah Barman","doi":"10.1155/tbj/7212120","DOIUrl":"10.1155/tbj/7212120","url":null,"abstract":"<p>Historically, HER2 status in invasive breast cancer has been categorized as HER2-positive (IHC 3+, IHC 2+/ISH+) or HER2-negative (IHC 0, IHC 1+, IHC 2+/ISH-). Patients meeting IHC 0 with membrane staining (HER2-ultralow) criteria may benefit from HER2-targeted therapies such as trastuzumab deruxtecan. This cohort study assessed the prevalence of HER2-ultralow expression by re-scoring HER2 IHC slides using Mayo Clinic electronic health record data. Three hundred patients with advanced breast cancer (Stages III-IV) and documented HER2 IHC 0 status (January 2017–March 2023) were identified. One slide per patient was digitized and independently re-scored by two Mayo Clinic pathologists following the 2023 ASCO-CAP guidelines, including tumor staining percentage to denote HER2-ultralow status. A sensitivity analysis was performed by a third independent pathologist. The re-scored patients had a mean age of 57.7 years (SD = 13.6). Most samples (95%, <i>n</i> = 285) remained scored IHC 0 by at least one pathologist; 60% of these met HER2-ultralow criteria per at least one pathologist. HER2-ultralow prevalence ranged from 43% to 45% per pathologist, with 57% overall interpathologist concordance. Samples with no observable staining comprised most of the concordant cases. Treatment patterns were similar between HER2-ultralow and no-staining groups; however, time to treatment failure (TTF) varied between groups across lines of therapy (LOT). In HR− positive cohorts, median TTF for LOT1 was 7.73 months in patients with HER2-ultralow versus 9.43 months with no observable IHC staining. In HR− negative cohorts, median TTF was 5.00 months for HER2-ultralow versus 3.17 months with no observable IHC staining. Similar TTF trends were observed in LOT2-LOT3. Approximately three in five samples originally classified as IHC 0 met HER2-ultralow criteria, suggesting many patients may benefit from HER2-directed therapy if reclassified. These findings highlight potential challenges of identifying HER2-ultralow expression and suggest the need for enhanced pathologist training, adherence to best practices, and integration of digital pathology and artificial intelligence solutions.</p><p><b>Trial Registration:</b> ClinicalTrials.gov_identifier: NCT03734029</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7212120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Clinical Trial of Honghua Xiaoyao Pills for the Treatment of Liver Depression and Haemostasis-Type Hyperplasia of Mammary Glands: A Single-Centre, Single-Arm Study","authors":"Li Zheng,&nbsp;Wei Liu,&nbsp;Jia-Ying Qiu,&nbsp;Yang Zhao,&nbsp;Xiao-Feng Li,&nbsp;Zhi-Gang Zhou,&nbsp;Jiang-Tao Wang,&nbsp;Yu Cui,&nbsp;Xiao-Jun Zhang","doi":"10.1155/tbj/3499662","DOIUrl":"10.1155/tbj/3499662","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hyperplasia of mammary glands (HMG) is a common benign disease of the female breast.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to observe the clinical efficacy and safety of Honghua Xiaoyao pills in the treatment of liver depression and haemostasis-type HMG, as well as their impact on menstruation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sixty patients diagnosed with liver depression and haemostasis-type HMG in the breast disease department of our hospital were selected as the study participants. The treatment involved oral administration of Honghua Xiaoyao pills: four pills per dose, three times a day, for a duration of 3 months without interruption during menstruation. Hormones, Western painkillers and similar Chinese herbal medicines were prohibited during the trial. Changes in breast pain, breast masses, menstrual volume and safety indicators were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three patients were lost to follow-up after 2 months of treatment, and four patients voluntarily withdrew from the study. The changes in breast pain scores, breast mass size scores and breast mass texture scores relative to baseline and their respective change rates showed statistically significant differences (<i>p</i> &lt; 0.0001). Changes in lower abdominal distension, breast distension, menstrual blood clots, chest tightness/discomfort and emotional scores relative to baseline were also statistically significant (<i>p</i> &lt; 0.0001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Honghua Xiaoyao pills are effective in reducing breast pain, shrinking breast masses and improving lower abdominal distension, breast distension, menstrual blood clots, chest tightness/discomfort and emotional symptoms in patients with liver depression and haemostasis-type HMG.</p>\u0000 \u0000 <p><b>Trial Registration:</b> International Traditional Medicine Clinical Trial Registry: ITMCTR2024000165</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/3499662","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis","authors":"Dandan Yu,&nbsp;Chengjun Zhu,&nbsp;Sujin Yang,&nbsp;Dandan Wang,&nbsp;Xiaoxiang Guan","doi":"10.1155/tbj/5088737","DOIUrl":"https://doi.org/10.1155/tbj/5088737","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Liver metastasis is a key adverse prognostic factor in breast cancer patients. This research was aimed to assess the development, risk factors, and prognostic determinants of breast cancer liver metastasis (BCLM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed the data of breast cancer from the Surveillance, Epidemiology, and End Results (SEER) (<i>N</i> = 560,908) and Jiangsu Province Hospital (JSPH) database (<i>N</i> = 294). The risk factors for BCLM were identified via multivariate logistic regression, and overall survival (OS) was assessed with Kaplan–Meier (KM) survival curves and Cox regression models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the SEER cohort, liver metastasis attacked 1.3% of patients, and the highest incidence was found in the HR−/HER2+ subtype (4.4%). The risk factors for BCLM include young age, high pathological grade, concurrent bone, lung or brain metastasis, and HER2-positive or triple-negative subtype. The median OS of BCLM patients was short (SEER: 22 months; JSPH: 33.5 months). OS was shorter in patients with concomitant metastasis to other organs or with HER2-negative subtype. Hepatic resection remarkably prolonged survival (SEER: 90 vs. 35 months; JSPH: not reached vs. 31.3 months). In the JSPH cohort, molecular subtype changed in 27.5% of patients during metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The occurrence of BCLM is affected by age, tumor grade, other organ involvement, and molecular subtype. Survival was improved in BCLM patients with liver-only metastasis, HER2-positive subtype, or those who underwent hepatic resection. The number and molecular characteristics of liver metastasis are important prognostic predictors, and receptor conversion highlights the need for reassessment of therapeutic strategies during metastatic progression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/5088737","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148282557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Hypofractionated Radiotherapy in Patients With Ductal Carcinoma In Situ (DCIS)","authors":"Reza Samiee,&nbsp;Mohammadamin Kharaghani,&nbsp;Amirhossein Shahsavand,&nbsp;Shayan Forghani,&nbsp;Mehrdad Mozafar,&nbsp;Negin Safari Dehnavi,&nbsp;Zahra Ghanbari,&nbsp;Luca Nicosia,&nbsp;Fatemeh Jafari","doi":"10.1155/tbj/9456822","DOIUrl":"10.1155/tbj/9456822","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To synthesize the available evidence on the oncologic outcomes, toxicity, and cosmesis of hypofractionated whole-breast irradiation (HF-WBI) in patients with ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, Embase, and Web of Science were searched from inception until July 12, 2025. We included studies of DCIS patients treated with BCS followed by HF-WBI (fraction size &gt; 2.0 Gy). Both comparative studies (against conventional fractionation [CF]) and single-arm studies reporting outcomes for HF-WBI alone were included. Pooled incidence rates for outcomes from single-arm studies and pooled hazard ratios (HRs) or odds ratios (ORs) from the limited comparative studies were calculated using random-effects models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nineteen studies were included. Local control and overall survival were excellent and equivalent between HF-WBI and CF-WBI. The pooled HR for local recurrence comparing ultrahypofractionation to CF was 0.89 (95% CI 0.64–1.24). HF-WBI significantly reduced the odds of acute dermatitis (OR 0.22, 95% CI 0.13–0.35). Late toxicities were infrequent (e.g., telangiectasia: 2%, 95% CI 0%–5%). Good/excellent cosmesis was reported in 90% (95% CI 84%–94%) of patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HF-WBI is a safe and effective treatment for DCIS, achieving oncologic outcomes equivalent to CF while offering improved tolerability, reduced acute skin toxicity, and excellent cosmetic results. These benefits, combined with increased convenience and potential cost savings, support the integration of HF-WBI into standard practice for DCIS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9456822","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Opinions on Postoperative Complications in Breast Cancer Surgery After Neoadjuvant Chemotherapy: A Descriptive Study Through Structured Interviews With Surgeons in Austria","authors":"Carmen Leser,&nbsp;Rebecca Eisl,&nbsp;Georg Dorffner,&nbsp;Fiona Kabashi,&nbsp;Daphne Gschwantler-Kaulich,&nbsp;Christine Deutschmann,&nbsp;Sabine Danzinger,&nbsp;Rupert Koller","doi":"10.1155/tbj/6589301","DOIUrl":"10.1155/tbj/6589301","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neoadjuvant chemotherapy (NACT) is an important component in preparing breast cancer patients for surgery. Its impact on postoperative complications, such as wound infections and bleeding, remains unclear. While most studies show no increase in complication rates, factors such as smoking may elevate risk. Understanding surgeons’ perspectives on bleeding and related influences is therefore essential.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study used a questionnaire on bleeding and wound healing. After ethical approval in Vienna and Burgenland, 33 surgeons were recruited. Data were collected between July and December 2022 through interviews or self-administered questionnaires and analyzed descriptively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 63.6% of surgeons reported recognizing NACT-treated patients intraoperatively. Perceptions of blood loss varied, with some noting no difference and others reporting increased bleeding. The influence of tumor size and smoking was debated, with no clear consensus. Most surgeons did not observe prolonged operative times. Challenges in axillary dissection and sentinel lymph node identification were reported, particularly after NACT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Surgeons’ views on the impact of NACT in breast surgery vary considerably. These findings highlight the complexity of integrating NACT into surgical practice and the need for further research to improve training, patient counseling, and evidence-based guidelines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6589301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148139876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}